FDA Awards Kemp Proteins Contract to Develop Monoclonal Antibodies for...

The FDA’s Laboratory of DNA Viruses will use the antibodies in the design of in-vitro assays for potency release of SARS-CoV-2 and Influenza vaccines.(PRWeb October 17, 2022)Read the full story at https://www.prweb.com/releases/fda_awards_kemp_proteins_contract_to_develop_monoclonal_antibodies_for_sars_cov_2_and_influenza_vaccine_potency_assays/prweb18961008.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news